Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Calliditas Therapeutics AB

www.pharmalink.se

Latest From Calliditas Therapeutics AB

Finance Watch: Genmab Launches This Year's Biggest Biopharma IPO In The US

Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.

Business Strategies Financing

Asia Deal Watch: Everest Licenses Asia Rights To Calliditas’ IgA Nephropathy Candidate

While an orphan indication in the US and EU, IgAN accounts for 40% of glomerular disease in China; deal also confers rights in Hong Kong, Macau, Taiwan, Singapore. Also, Y-Biologics teams with Dualogics on bispecific antibodies for cancer.

Business Strategies Deals

Calliditas IPO To Support Phase III Berger's Disease Study

Calliditas is aiming to raise new funding in an IPO and listing on Nasdaq Sweden to support late-stage clinical development and commercialization of its Berger's disease candidate, and studies in additional indications.

 

Financing Renal

Pipeline Watch: Phase III Progress With Tecentriq, Viaskin Peanut And Capalizumab

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals
See All

Company Information

  • Industry
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Renal System
  • Alias(es)
  • Pharmalink AB
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Calliditas Therapeutics AB
  • Senior Management
  • Renee Aguiar-Lucander, CEO
    Fredrik Johansson, CFO
    Jens Kristensen, PhD, CMO
  • Contact Info
  • Calliditas Therapeutics AB
    Phone: (46) 8 411 3005
    Wallingatan 26B
    Stockholm, SE-114 24
    Sweden
Advertisement
Advertisement
UsernamePublicRestriction

Register